Clinical Trial Update: Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase II study evaluating fractionated 90Y ibritumomab tiuxetan (Zevalin) as initial therapy for follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• ibritumomab tiuxetan (Zevalin) (ibritumomab tiuxetan)

Snippet

Sponsor: The Christie NHS Foundation Trust | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED